Compare TECX & NXJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TECX | NXJ |
|---|---|---|
| Founded | 2019 | 1999 |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.1M | 503.5M |
| IPO Year | N/A | N/A |
| Metric | TECX | NXJ |
|---|---|---|
| Price | $29.27 | $12.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $75.20 | N/A |
| AVG Volume (30 Days) | ★ 189.7K | 90.3K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.27% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.39 | $11.06 |
| 52 Week High | $35.99 | $12.90 |
| Indicator | TECX | NXJ |
|---|---|---|
| Relative Strength Index (RSI) | 50.66 | 55.04 |
| Support Level | $28.31 | $11.94 |
| Resistance Level | $31.88 | $12.76 |
| Average True Range (ATR) | 1.53 | 0.09 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 48.05 | 69.38 |
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.